On March 23, Lilly/BI announced the US launch of Glyxambi at pharmacies nationwide. This comes two months after FDA approval and represents the first SGLT-2 inhibitor/DPP-4 inhibitor fixed dose combination drug available in the US. Its main benefit is combining two different diabetes drugs into a single pill (in this case, Tradjenta and Jardiance) with one co-pay.